Tweed’s Comeback and a June Deadline: Canopy Growth’s Two-Front Battle

Canopy Growth launches Tweed brand overhaul in Canada as US DOJ reschedules medical cannabis, boosting stocks but limiting direct benefits for the Canadian firm.

The cannabis giant is juggling a brand overhaul at home with a pivotal regulatory hearing in Washington — and the market is watching both closely.

On April 23, Canopy Growth unveiled a complete repositioning of its flagship Tweed brand, rolling out new packaging, higher potency offerings, and a national summer campaign dubbed “There’s a Tweed for That.” Three fresh strains — Tropical Gelato Slushie, Citrus Candy Cake, and GMO Jet Fuel — join the lineup, alongside a new milled format slated for later this summer. The launch is timed to the Victoria Day weekend, traditionally the kickoff of Canada’s summer retail season and one of the busiest sales windows for licensed producers.

The move is more than a marketing refresh. Tweed has lost shelf space and consumer mindshare in a crowded Canadian market, and Canopy is betting that visible packaging windows, competitive pricing, and higher THC content can reverse that slide. The full portfolio now spans whole flower, milled flower, Quickies pre-rolls, liquid diamond vapes, and softgels.

But the brand relaunch is unfolding against a backdrop of regulatory noise south of the border. On the same day Canopy announced the Tweed overhaul, the US Department of Justice issued an order moving FDA-approved and state-licensed medical cannabis into Schedule III of the Controlled Substances Act. The directive, rooted in a December 2025 executive order from President Trump, triggered a brief rally across cannabis stocks — Tilray, Curaleaf, and Canopy all posted double-digit gains on Wednesday. Canopy shares surged from roughly $0.86 in late March to an intraday high of $1.51 before closing at $1.28, then slipped further as the market digested the order’s limitations.

The key takeaway: the DOJ order applies only to medical cannabis. Adult-use remains federally illegal, and the benefit is unevenly distributed. For Canopy, a Nasdaq-listed Canadian company that cannot directly hold US cannabis operations, the practical impact is indirect at best. Its economic interest in Canopy USA still sits off the balance sheet. The real prize — access to the US market — depends on future legislation, not this administrative step.

By April 27, Canopy shares were trading between $1.14 and $1.26, settling near $1.20. The stock has gained roughly 25% over the past month, but most of that move reflects sector-wide optimism around rescheduling rather than company-specific momentum. The 52-week range of $0.84 to $2.38 underscores just how far the stock has fallen from its peak — and how speculative it remains.

Operationally, there are signs of stabilization. In the third quarter of fiscal 2026 (ending December 31, 2025), consolidated net revenue held steady at C$75 million, flat year-over-year. The net loss nearly halved, while adjusted EBITDA loss narrowed to C$3 million — the third consecutive quarter of improvement, driven largely by lower administrative costs. Free cash outflow improved from C$28 million to C$19 million. The company holds C$371 million in cash, with a net cash position of C$146 million. A recapitalization in January 2026 pushed all debt maturities to at least 2031, though it diluted existing shareholders in the process.

The next major catalyst is the June 29 hearing before the US Drug Enforcement Administration, which will begin an accelerated administrative review of moving all cannabis — not just medical — from Schedule I to Schedule III. A decision is expected by July 15. Opposition groups like Smart Approaches to Marijuana have already signaled legal challenges, which could delay the process. For Canopy, that hearing represents the most significant regulatory lever on the horizon — but until the core business turns profitable, the stock remains a bet on policy tailwinds rather than operational strength.

The planned acquisition of MTL Cannabis is expected to lift gross margins into the mid-to-high 30% range, providing a foundation for the company’s target of positive adjusted EBITDA in fiscal 2027. Until then, Canopy is fighting a two-front war: rebuilding a brand at home while waiting for a policy breakthrough abroad.